Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cryoablation combined with sintilimab for melanoma liver metastases
ChiCTR2200061591Phase 2Recruiting
- Sponsor
- Sun Yat-sen University Cancer Center
- Start
- Jun 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sintilimab in melanoma and hepatic metastasis, sponsored by Sun Yat-sen University Cancer Center. Primary endpoint: 6-month progression-free survival rate. Started Jun 2022; status: recruiting.
02
Drugs
sintilimab
03
Conditions
melanomahepatic metastasis
Beyond the preview
Go deeper on ChiCTR2200061591.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200061591.